MAPT and Cognitive impairment: We identified nine joint independent components (ICs) for amyloid-β and tau in the analyses of 18F-Flutemetamol and 18F-Flortaucipir PET data in the entire sample of 117 subjects (26 amyloid-β negative cognitively normal subjects, 34 amyloid-β positive cognitively normal subjects, 21 patients with mild cognitive impairment, 36 patients with Alzheimer’s disease).